Investor sentiment was buoyed by eased concerns regarding ‘Liberation Day.’ Among individual stocks, Gold Road Resources saw its shares climb to an all-time high after rejecting a takeover bid from ...

Altech Batteries (ASX:ATC) has reached a funding agreement with its largest shareholder, Deutsche Balaton AG, allowing it to ...

HSBC Holdings is reportedly considering outsourcing parts of its fixed-income trading business as it seeks to reduce technology-related costs and keep pace with more agile, tech-driven competitors, ...

Ruakaka is one of several major projects in Meridian’s $3bn pipeline. Other initiatives include the 90MW Mt Munro Wind Farm, the 400MW Te Rahui Solar Farm in joint venture with Nova Energy, and a ...

Immutep (ASX:IMM) has dosed the first patient in its pivotal Phase III trial evaluating eftilagimod alfa (efti) for the treatment of advanced non-small cell lung cancer (NSCLC), marking a major ...

Investor optimism was further fuelled by reports suggesting that the administration’s tariff plans might be less extensive than initially feared, potentially mitigating the risk of a full-blown trade ...

Hyundai Motor Group has announced a major $21 billion investment in the United States over the next four years, marking its largest-ever commitment to the country. The move comes as the South Korean ...

SAP has overtaken Danish drugmaker Novo Nordisk to become Europe’s most valuable listed company, marking a major milestone for the German software group and a shift in investor sentiment from pharma ...

Tesla shares have jumped more than 11% on Monday, buoyed by renewed investor enthusiasm following comments from CEO Elon Musk ...

Helia (ASX:HLI) has announced it is likely to lose a cornerstone contract with the Commonwealth Bank of Australia, following CBA’s decision to enter exclusive negotiations with an alternative provider ...

Turkey’s Capital Markets Board has imposed a sweeping ban on short selling and loosened share buyback restrictions in an effort to stabilise markets following a sharp sell-off triggered by political ...

Opthea (ASX:OPT) has announced that its lead drug candidate sozinibercept has failed to meet primary endpoints in a phase 3 trial, raising serious concerns about the company’s future viability and its ...